CERVEAU GENESIS

In 2016, Cerveau was formed to advance MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become an acknowledged leading imaging biomarker for Tau pathologies, central to AD progression. Cerveau licensed MK-6240 from Merck and committed to establish a broad network of production facilities to support clinical research.

Through the Cerveau Users Group, Pharma companies and leading Academic centers gain access to MK-6240 for their cutting edge research, share non-competitive data with the entire Users Group and disclose breakthrough science as appropriate.

CERVEAU EVOLUTION

Dec 2016

Merck License

Feb 2017

Siemens
PETNET
Partnership

Jun 2017

MK-6240
IND Accepted
by FDA

Jul 2017

1st Dose
Supporting
Pharma Trial

Oct 2017

MK-6240
Global
Database
Opens

Dec 2017

8 Pharma
Licenses

May 2018

471 Human
Exposures

Dec 2018

25 Trials
Initiated

May 2019

1st subject in
MK-6240
ALERT
Longitudinal
Trial

Jun 2019

1575 Human
Exposures

Oct 2019

1st Subject in
Japan Phase 1
Trial

To Date

~ 4500
Human
Exposures(12
Pharma
Licenses)

CERVEAU TEAM

This dramatic growth has been enabled by the assembly of a team of highly experienced subject matter experts covering all areas essential to the production and management of MK-6240 and its associated image data.